Your browser doesn't support javascript.
loading
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez, Joaquin; Alonso, Rafael; Wong, Sandy W; Rios, Rafael; Shah, Nina; Ruiz-Heredia, Yanira; Sanchez-Pina, Jose Maria; Sanchez, Ricardo; Bahri, Natasha; Zamanillo, Irene; Poza, Maria; Buenache, Natalia; Encinas, Cristina; Juarez, Luis; Miras, Fatima; Collado, Luis; Barrio, Santiago; Martin, Thomas; Cedena, Maria Teresa; Wolf, Jeffrey.
Afiliación
  • Martinez-Lopez J; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain. jmarti01@ucm.es.
  • Alonso R; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA. jmarti01@ucm.es.
  • Wong SW; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
  • Rios R; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA.
  • Shah N; Hematology Department, Hospital Virgen de Las Nieves, Granada, Spain.
  • Ruiz-Heredia Y; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA.
  • Sanchez-Pina JM; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
  • Sanchez R; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
  • Bahri N; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
  • Zamanillo I; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA.
  • Poza M; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
  • Buenache N; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
  • Encinas C; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
  • Juarez L; Hematology Department, Hospital General Univesitario Gregorio Marañon, Madrid, Spain.
  • Miras F; Hematology Department, Hospital General Univesitario Gregorio Marañon, Madrid, Spain.
  • Collado L; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
  • Barrio S; Medicine Department, Complutense University, Madrid, Spain.
  • Martin T; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
  • Cedena MT; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA.
  • Wolf J; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
J Hematol Oncol ; 14(1): 126, 2021 08 17.
Article en En | MEDLINE | ID: mdl-34404440
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasia Residual / Mieloma Múltiple Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasia Residual / Mieloma Múltiple Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: J Hematol Oncol Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: España